All In Biotech

Drug Trial Radar · NCT05562830

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Nov 16, 2022

Primary completion

Feb 26, 2029

Study completion Feb 26, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease is resistant to treatment with programmed cell death-1/ligand 1 (PD-1/L1) inhibitors. The protocol infrastructure will enable the rolling assignment of investigational treatments.

Conditions

  • Urothelial Carcinoma

Interventions

  • Zilovertamab vedotinBiological

    Administered via intravenous (IV) infusion on day 1 and day 8 of Q3W cycles

  • PembrolizumabBiological

    Administered via IV infusion on Day 1 of each 6 week cycle.

  • MK-3120Biological

    Administered as an IV infusion on Day 1, Day 15, and Day 29 of each 6 week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Experienced At Least One Adverse Event (AE)Time frame: Up to approximately 5 years
  2. Percentage of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 5 years
  3. Arm A: Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 2 years
  4. Arm B: ORR as Assessed by InvestigatorTime frame: Up to approximately 2 years

Locations

28 sites in 11 countries. Site status is shown where the registry gives one.

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045)

    Orange, California

  • University of California San Francisco ( Site 1044)

    San Francisco, California

  • Anschutz Cancer Pavilion ( Site 1017)

    Aurora, Colorado

  • University of Chicago Medical Center ( Site 1037)

    Chicago, Illinois

  • Indiana University Melvin and Bren Simon Cancer Center ( Site 1011)

    Indianapolis, Indiana

  • Siteman Cancer Center ( Site 1038)

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center ( Site 1031)

    New York, New York

  • Cleveland Clinic-Taussig Cancer Center ( Site 1036)

    Cleveland, Ohio

  • UPMC Hillman Cancer Center ( Site 1014)

    Pittsburgh, Pennsylvania

  • Huntsman Cancer Institute ( Site 1041)

    Salt Lake City, Utah

  • Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 1952)

    Brisbane, Queensland, Australia

  • Princess Margaret Cancer Centre ( Site 1106)

    Toronto, Ontario, Canada

  • FALP-UIDO ( Site 1151)

    Santiago, Region M. de Santiago, Chile

  • Bradford Hill ( Site 1155)

    Santiago, Region M. de Santiago, Chile

  • Rigshospitalet-Dept. of Oncology ( Site 1701)

    Copenhagen, Capital Region, Denmark

  • Rambam Health Care Campus-Oncology ( Site 1501)

    Haifa, Israel

  • Rabin Medical Center-Oncology ( Site 1504)

    Petah Tikva, Israel

  • Sheba Medical Center-ONCOLOGY ( Site 1503)

    Ramat Gan, Israel

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1406)

    Naples, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1408)

    Milan, Lombardy, Italy

  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 1302)

    Amsterdam, North Holland, Netherlands

  • Severance Hospital, Yonsei University Health System ( Site 1903)

    Seoul, South Korea

  • Asan Medical Center ( Site 1901)

    Seoul, South Korea

  • Samsung Medical Center ( Site 1902)

    Seoul, South Korea

  • Hospital Clinico San Carlos ( Site 1765)

    Madrid, Spain

  • Hospital Universitari Vall d'Hebron ( Site 1767)

    Barcelona, Catalonia, Spain

  • St Bartholomew's Hospital ( Site 1206)

    London, London, City of, United Kingdom

  • ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 1201)

    London, London, City of, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.